We are exclusively a Plaintiff’s firm. Our attorneys handle any type of serious injury case. From injuries caused by dog bites to those caused by environmental toxins, we’ll fight for compensation from the responsible party. We can also answer your important questions about how personal injury cases work and what to expect.
The pharmaceutical industry is powerful. Though they manufacture drugs that may help patients, they are also concerned about the bottom line. As a result, some drugs make it through the pipeline before testing has been completed, or with side effects and health risks minimized or ignored. Drugs that have been aggressively marketed in this way are often the center of recalls, but for some patients, these recalls come too late. Dangerous health issues such as heart attacks, strokes, kidney and liver damage, diabetes, and even suicide may be the result of taking a defective pharmaceutical. Recent FDA recalls, or black box warnings – the strongest warning given before a recall is put into effect – have affected many drugs for many different conditions. If you or a loved one has been injured or sickened by taking something meant to help, please contact the drug lawsuit attorneys at Taylor Martino.
You may have heard in the news that Zantac (ranitidine) has been linked to cancer. Lawsuits against Zantac manufacturers allege the drug contains a cancer-causing chemical called N-Nitrosodimethylamine (NDMA). Receiving a cancer diagnosis is troubling enough on its own. Our attorneys are knowledgeable about legal claims involving drug injuries and we are actively evaluating Zantac Injury Lawsuits.
The acceptable daily intake of NDMA is 96 mg or 0.32 parts per million for ranitidine. Exceeding that amount can expose patients to serious health risks. WHO reported that exposure to high levels of NDMA is believed to cause stomach and colorectal cancers. It is also toxic to the liver, even in small amounts. Zantac lawsuits show that ranitidine can break down within the body to form NDMA at levels well in excess of the permissible daily intake. Plaintiffs allege they developed cancer as a result of exposure to the high levels of NDMA formed by Zantac.
FDA testing found evidence of NDMA in certain ranitidine medicines, including Zantac. NDMA exposure can potentially affect the bladder, brain, liver, kidneys, lungs and stomach, per a report by the World Health Organization (WHO). WHO also classifies NDMA as a B2 carcinogen or “probable human carcinogen,” and the U.S. National Toxicology Program lists the known environmental contaminant as a compound that is “reasonably anticipated to be a human carcinogen.”
The law firm of Taylor Martino is actively evaluating personal injury and wrongful death cases caused by the use of Zantac. We intend to hold the drug makers accountable for allegedly concealing the Zantac cancer link and putting profit before people. An experienced attorney can help evaluate your case and assess your specific damages to get you the maximum compensation you need for your recovery and for your family. Find Out If You Qualify >>
Amidst concerns announced by the U.S. Food and Drug Administration (FDA) that the medication is possibly linked to an increased occurrence of cancer, in early 2020 Belviq (lorcaserin) was voluntarily recalled from the US market by its’ maker Eisai Inc. The decision came after the analysis of results retrieved from a long-term study conducted after Belviq hit the market, in order to determine the cardiovascular effects of the drug.
What the study revealed was that patients taking Belviq were more likely to develop cancer over the course of five years, than participants taking a placebo. Certain types of cancer, including pancreatic, colorectal and lung cancers, were more commonly diagnosed in Belviq-users. Patients and their families who developed cancer after taking Belviq, are now suing the drug’s manufacturer for failing to adequately warn consumers of the drug’s safety risks.
The law firm of Taylor Martino is actively evaluating personal injury, cancer, and wrongful death cases caused by the use of Belviq. We intend to hold the drug makers accountable for allegedly concealing the Belviq cancer link and putting profit before people. An experienced attorney can help evaluate your case and assess your specific damages to get you the maximum compensation you need for your recovery and for your family. Find Out If You Qualify >>
Valsartan has been gaining attention since late 2018, due to the link between the generic drug meant to treat blood pressure and an increased risk of cancer and liver damage. In addition to treating blood pressure, valsartan, classified as an angiotensin II receptor blocker (ARB), is used to treat heart failure. It can also help to improve a person’s chances of survival after a heart attack.
Valsartan works by blocking the action of certain natural substances in the body called angiotensin II receptors that narrow or tighten the blood vessels. By stopping this action, the heart can pump blood more efficiently and easily throughout the body.
People who filed valsartan lawsuits allege they “developed cancer as a result of using valsartan containing
NDMA or NDEA impurities. NDMA and NDEA are classified as “probable human carcinogens,” meaning
there is a likelihood they can cause cancer in humans, especially at high levels of exposure. The FDA
noted that the amounts of the chemical substances found in contaminated batches of valsartan exceeded
acceptable daily limits for human consumption.
The law firm of Taylor Martino is actively evaluating personal injury and wrongful death cases resulting from valsartan use. We intend to hold the drug makers accountable for allegedly concealing valsartan’s link to cancer and other possible injuries. Drug manufacturers must be held responsible when they willfully put profit before people thereby harming those who are trusting them to be considerate of their health and wellbeing. Find Out If You Qualify >>
People suing Bristol-Myers Squibb and AstraZeneca over Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin HCI extended release) are alleging that these drugs have caused serious cardiac complications and possibly death.
According to the lawsuits, Bristol-Myers Squibb and AstraZeneca ignored patient safety and began selling Onglyza and Kombiglyze XR in 2009 and 2010 before completing a recommended study by the U.S. Food and Drug Administration, meant to assess cardiac risks in the Type 2 diabetes drugs.
After the companies finally conducted the study and found the drugs increased the risk of heart failure, the FDA released a Drug Safety Communication on April 5, 2016, to warn the public about the risk. But the warning may have come too late for hundreds of thousands of patients already taking the drugs for years.